Advanced Search
Contact | Corporate | Help

A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome

Sponsors:
  • Novartis
Phases:
  • Phase I
  • Phase II
IndicationsAcronym:
  • Healthy Volunteers
  • Atopic Dermatitis
  • Netherton Syndrome
Age Groups:
  • Adult
Gender:
Both
Names:
  • Drug: BPR277 ointment (controlled application)
  • Drug: Placebo (Vehicle)
  • Drug: BPR277 ointment
  • Drug: Placebo (Vehicle)
  • Drug: BPR277
  • Drug: Placebo (Vehicle)
Enrollment:
65

Additional information about NCT01428297.


SourceSolution © 2008-2012